PDE5A and benign prostatic hyperplasia: Treatment options for LUTS-BPH have since increased with regulatory approval of tadalafil 5mg once daily, a long-acting phosphodiesterase type 5 (PDE-5) inhibitor, initially in the US in 2011 and subsequently in the EU and other major territories in 2012 [3].